VYEPTI for chronic migraine

Explore the results:

PROMISE-2 was a parallel-group, double-blind, placebo-controlled global trial to evaluate the efficacy and safety of VYEPTI for the preventive treatment of chronic migraine in adults. A total of 1072 patients were randomized and received placebo (n=366), VYEPTI 100 mg (n=356), or VYEPTI 300 mg (n=350) every 3 months for 6 months.1

VYEPTI support icon

VYEPTI CONNECT: Your direct link to access support

IV migraine treatment icon

VYEPTI is just one 30-minute IV treatment given every 3 months

References:
  1. VYEPTI [package insert]. Deerfield, IL: Lundbeck Seattle BioPharmaceuticals, Inc.
  2. Kudrow D, Lipton R, Silberstein S, et al. Eptinezumab for prevention of chronic migraine: results of 2 Infusions in the phase 3 PROMISE-2 (PRevention Of Migraine via Intravenous Eptinezumab Safety and Efficacy–2) trial. Poster presented at: 71st American Academy of Neurology (AAN) Annual Meeting; May 4-10, 2019; Philadelphia, PA. 10-006.
  3. Data on file. Deerfield, IL: Lundbeck Seattle BioPharmaceuticals, Inc.
  4. Lipton RB, Goadsby PJ, Azimova J, et al. A phase 3 Study to Evaluate Eptinezumab for the Preventive Treatment of Chronic Migraine: Results of the PROMISE-2 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy–2) Trial. Poster presented at: 60th Annual Scientific Meeting of the American Headache Society (AHS); June 28-July 1, 2018; San Francisco, CA. PFO2.
  5. Saper J, Wilks K, Chakhava G, et al. Eptinezumab for the prevention of episodic migraine through 1 year: results from the phase 3 PROMISE-1 (PRevention Of Migraine via Intravenous Eptinezumab Safety and Efficacy–1) trial. Poster presented at: 71st American Academy of Neurology (AAN) Annual Meeting; May 4-10, 2019; Philadelphia, PA. 538.003.
  6. Winner P, McAllister P, Cady R, Snapinn S, Hirman J, Kassel E. Migraine-free months in patients with episodic or chronic migraine treated with eptinezumab: results from the PROMISE-1 and PROMISE-2 trials. Poster presented at: 61st Annual Scientific Meeting of the American Headache Society (AHS); July 11-14, 2019; Philadelphia, PA. P217LB.
  7. Lipton RB, McGill L, Hirman J, Biondi D, Cady R. Patient global impression of change related to improvement in most bothersome symptom following treatment with eptinezumab. Poster presented at: ISPOR 2019; May 18-22, 2019; New Orleans, LA. PND81.
IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.